Fig. 1
From: No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone
a-b qRT-PCR and western blot analyses, respectively, reveal heterogeneous expression of IGF pathway members in chondrosarcoma cell lines. c Immunoprecipitation with IRS1 followed by a western blot for phospho-IRS1 reveals pathway activity in two out of three chondrosarcoma cell lines tested. d Evaluation of IGF1R downstream targets reveals an effect of OSI-906 on IGF1R and pAkt but not on pS6 and disphosphorylated ERK-1&2. Cell lines were treated for 72Â hours with DMSO, 1Â ÎĽM OSI-906 and/or 50Â ng/ml IGF1